The good news for Eli Lilly: Its experimental late-stage psoriasis drug has topped Pfizer and Amgen's blockbuster Enbrel in a head-to-head study. The not-so-good news: It's not the only one.
Jazz Pharmaceuticals and Boston Scientific have begun using Box as their main platform for managing and collaborating on content.
Eli Lilly has posted a superior therapeutic profile for its experimental late-stage psoriasis drug ixekizumab when compared with Pfizer's Enbrel in a head-to-head study.
Following fast on the heels of a rival development team at Novartis, Eli Lilly has posted a superior therapeutic profile for its experimental late-stage psoriasis drug ixekizumab compared to Pfizer's Enbrel in a head-to-head study. And Lilly says the results are good enough to back a regulatory filing in the first half of 2015 for its IL-17A therapy as it races to gain some new approvals following a punishing onslaught of generic competition to its top drug franchises.
Eli Lilly won't be able to sell its Lantus copycat--dubbed Basaglar--for at least 30 months because of a patent fight with Sanofi.
Eli Lilly has won a "tentative" FDA approval for its knockoff of Sanofi's Lantus, but don't look for it at a pharmacy anytime soon. The insulin glargine injection--to be marketed as Basaglar eventually in the U.S.--faces an automatic 30-month stay after Sanofi filed a suit against Lilly and its partner Boehringer Ingelheim claiming patent infringement.
The executive team here at the rapidly expanding headquarters of Novo Nordisk doesn't pull many punches. CEO Lars Rebien S ø rensen is a competitive sort who tends to be blunt, aggressive and forward-thinking; projecting a confident attitude that is reflected by the rest of the execs and right down the line to 40,000 rank-and-file employees around the world.
Eli Lilly is consolidating all of its animal enzyme manufacturing operations to the U.K. A spokesperson for the Indianapolis-based company has announced that it will now close an Elanco plant in Terre Haute, IN, as part of the move across the pond.
Without the safety concerns that plague its competitors, Jardiance may be able to make a splash.
Just because a drug is third to market doesn't mean it's not a viable player--especially if it has safety on its side. Just ask Biogen Idec, whose Tecfidera has quickly eclipsed its predecessors to take the multiple sclerosis market by storm. But is that type of launch in the cards for Eli Lilly and Boehringer Ingelheim's diabetes med Jardiance?